Abstract 2257: Phase II study of dual immune checkpoint blockade (ICB) with durvalumab (Durva) plus tremelimumab (T) following palliative hypofractionated radiotherapy (SBRT) in patients (pts) with microsatellite-stable (MSS) metastatic colorectal cancer (mCRC) progressing on chemotherapy: NSABP FC-9
Year: 2019
Type: conference-abstract
Authors: James J. Lee, Greg Yothers, Thomas J. George, Marwan G. Fakih, Atrayee Basu Mallick, Edith P. Mitchell, James L. Wade, John C. Krauss, Omar R. Kayaleh, Dwight E. Heron, Carmen J. Allegra, Corey Lipchik, Huichen Feng, Marion Joy, Ashok Srinivasan, Katherine L. Pogue-Geile, Peter C. Lucas, Sarah E. Warren, Alessandra Cesano, Samuel A. Jacobs
Institutions: University of Pittsburgh, UPMC Hillman Cancer Center, University of Pittsburgh Medical Center, NSABP Foundation, University of Florida Health, City Of Hope National Medical Center, City of Hope, Thomas Jefferson University Hospital, Decatur Memorial Hospital, University of Michigan, Orlando Health, Nanostring Technologies (United States)
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4246984925